Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201315, China.
Shanghai Key Laboratory of radiation oncology (20dz2261000), Shanghai, 201315, China.
BMC Cancer. 2024 Jun 18;24(1):742. doi: 10.1186/s12885-024-12471-8.
Nasopharyngeal adenoid cystic carcinoma (NACC) is a relatively rare salivary gland tumor that is generally associated with poor outcomes. High-dose radiotherapy is a key treatment for patients with NACC. This study reported the long-term efficacy and safety of particle beam radiation therapy (PBRT) for NACC.
Twenty-six patients with nonmetastatic NACC who received definitive PBRT alone were included in this retrospective study. The majority of patients (92.3%) had locally advanced disease. Twenty-five (96.15%) patients received intensity-modulated proton radiotherapy (IMPT) followed by a carbon ion radiotherapy (CIRT) boost, and one patient received CIRT alone. Overall survival (OS), local control (LC), regional control (RC), and distant metastasis control (DMC) rates were calculated via the Kaplan-Meier method.
The median follow-up time was 46.95 months for the entire cohort. Seven patients experienced local recurrence, and one patient experience neck lymph node recurrence. The 3- and 4-year OS, LC, RC, and DMC rates were 100% and 91.7%, 92.3% and 84.6%, 95.8% and 87.8%, and 90.2% and 71.3%, respectively. A total of 91.3% of the patients achieved complete remission of gross tumors at 1 year after PBRT. Severe acute toxicity was observed in only two patients. A grade 4 decrease in visual acuity was observed in one patient with orbital apex invasion. No late grade 3 or 5 toxicity was observed.
Definitive PBRT provided a satisfactory 4-year OS for patients with locally advanced NACC. The toxicity was acceptable and mild. Further follow-up is necessary to confirm the efficacy and safety of definitive PBRT for patients with NACC.
鼻咽腺样囊性癌(NACC)是一种相对罕见的唾液腺肿瘤,通常预后较差。高剂量放疗是 NACC 患者的关键治疗方法。本研究报告了粒子束放疗(PBRT)治疗 NACC 的长期疗效和安全性。
本回顾性研究纳入了 26 例接受单纯根治性 PBRT 的非转移性 NACC 患者。大多数患者(92.3%)患有局部晚期疾病。25 例(96.15%)患者接受强度调制质子放疗(IMPT)后行碳离子放疗(CIRT)加量,1 例患者单独接受 CIRT。通过 Kaplan-Meier 法计算总生存率(OS)、局部控制率(LC)、区域控制率(RC)和远处转移控制率(DMC)。
全队列的中位随访时间为 46.95 个月。7 例患者出现局部复发,1 例患者出现颈部淋巴结复发。3 年和 4 年的 OS、LC、RC 和 DMC 率分别为 100%和 91.7%、92.3%和 84.6%、95.8%和 87.8%、90.2%和 71.3%。PBRT 后 1 年,91.3%的患者实现了大体肿瘤完全缓解。仅 2 例患者出现严重急性毒性。1 例眼眶尖部侵犯患者出现视力 4 级下降。未观察到晚期 3 级或 5 级毒性。
根治性 PBRT 为局部晚期 NACC 患者提供了令人满意的 4 年 OS。毒性可接受且轻微。需要进一步随访以确认 PBRT 治疗 NACC 患者的疗效和安全性。